首页
登录
职称英语
Small, pink and very ugly. Hardly the qualities of a star, but they describe
Small, pink and very ugly. Hardly the qualities of a star, but they describe
游客
2025-05-08
21
管理
问题
Small, pink and very ugly. Hardly the qualities of a star, but they describe the deformed mouse that was the media darling at a recent science exhibition in Beijing. With a complex tissue structure in the shape of a human ear grafted on to its back, the rosy rodent was a stunning symbol of the serious strides China is making in the field of biotechnology.
China is fast applying the latest life-science techniques learned from the West m aggressively pursue genome research. It’s establishing its own centers of technical excellence to build a scientific base to compete directly with the United States and Europe. With a plentiful supply of smart young scientists at home and lots of interest abroad biotechnology is on the brink of a boom in China and in the view of foreign scientists, Beijing is playing a clever hand, maximizing the opportunities open to them.
For the moment, the cooperation exists mostly with Europe and the U. S. But Asia’s other biotech leaders, Japan, Singapore and Korea, also are recognizing China’s potential as an attractive low-cost base to conduct research. These partnerships--and China’s advancement in the field of biotechnology--could help benefit the rest of Asia: China’s rapid progress in improving crop yields will address food-security concerns in the region. In addition, China is more likely to focus on developing cheap technology that its predominantly poor population--and those of other Asian countries--can afford.
There remain, however, serious barriers to the development of a strong biotech industry. Among them are a poor domestic legal framework, weak enforcement of intellectual-property rights and loose adherence to international standards. China is a signatory of the International Bio Safety Protocol, which should mean adherence to global standards governing the conduct of field trims. But some observers are skeptical. "The regulations look good, but I haven’t met one scientist who believes they are being fully adhered to," says a European science analyst.
If shortcuts are taken, then some of the recent scientific achievements trumpeted in the official press may never make it to market. But no matter how strict lab tests are, other problems lie in wait. For example, there is a number of tasks it would take years to fulfill in the patents office, says one lawyer, leaving innovators with little protection if they take a product to market in China. [br] In the field of biotechnology China is thought to ______.
选项
A、have been making an utmost effort learning from the West
B、have become a country among the advanced
C、have been able to rival the United States and Europe
D、have launched a biotechnological revolution
答案
A
解析
转载请注明原文地址:https://tihaiku.com/zcyy/4067307.html
相关试题推荐
Small,pinkandveryugly.Hardlythequalitiesofastar,buttheydescribe
Small,pinkandveryugly.Hardlythequalitiesofastar,buttheydescribe
Psychologistshaverecentlymountedanoffensiveagainstwhattheydescribeasn
OneworddescribeswhatmakesSingaporework:discipline.A、punishmentB、regulati
Anoldwomanwasbadlyhurtin______thepolicedescribeasanapparentlymotiv
(It)wouldbe(hardly)forMrsSharptofind(a)man(ofparts)aroundher.A、It
Furthereducationisofficially(described)asthepost-secondarystageofeduca
AnaisNin’sdiariesareoftenscandalous,probablybecauseshedescribesherself
Theword"foolish"istoomildtodescribeyourbehavior,Iwouldpreferthewor
Theword"foolish"istoomildtodescribeyourbehavior,Iwouldpreferthewor
随机试题
Thenexttrain______thestationat11o’clock.A、leavesB、hasleftC、leftD、lea
Onlinebillpaycanhelpyoumanageyourbillswithouthavingtoworryabout
Becarefulwhatyousayaroundyourdog.Itmightunderstandmorethanyout
我国现存最大的类书是( )。A.《永乐大典》 B.《古今图书集成》 C.《
下列票据中,不属于增值税合法扣税凭证的是()。A.增值税专用发票 B.海关
2018年1月1日,甲公司以银行存款1100万元购入乙公司当日发行的面值为100
患者女,29岁,初孕妇。孕40周,在分娩中发生羊水栓塞。护理措施不妥的是A.解除
马者所以命形也;白者所以命色也。命色者非命形也,故曰白马非马。”从唯物辩证法的观
下列关于低经营杠杆企业的说法中,正确的选项是()。A.固定成本占有较大的比例
心境障碍一般具有以下哪个特点?( )A.一次发作,永不缓解 B.发作一次,加
最新回复
(
0
)